Guardant Health Inc. (NASDAQ: GH) saw its stock surge 5.66% in after-hours trading on Wednesday following the release of its second-quarter 2025 financial results, which surpassed analyst expectations. The precision medicine company, focused on improving cancer care, not only reported strong quarterly performance but also raised its full-year revenue guidance.

For Q2 2025, Guardant Health reported revenue of $232.10 million, representing a 31% increase year-over-year and beating the consensus estimate of $211.20 million. The company's adjusted earnings per share (EPS) came in at -$0.44, significantly better than the expected -$0.79. Additionally, adjusted EBITDA was -$51.90 million, outperforming the estimated -$58.10 million.

The strong performance was driven by several factors, including a 30% increase in oncology test volume and improved reimbursement rates. The company also noted strong demand for its Shield tests, contributing to revenue growth in the screening segment. Based on these positive results, Guardant Health raised its 2025 revenue guidance to $915-$925 million. The company now expects oncology revenue to grow 20% year-over-year, with screening revenue projected at $55-$60 million for the year. The biopharma and data segment is anticipated to see growth in the mid-teens for 2025.